Most notably, immune checkpoint blockades (ICBs) targeting PD-1/PD-L1 and CTLA-4 have shown clinical activity in mesothelioma, leading to the approval of nivolumab (NIVO) (anti-PD-1) plus ipilimumab (IPI) (anti-CTLA-4) as a first-line option for unresectable PM [4]. The gene discussed is CTLA4; the disease is mesothelioma.